GILD · Gilead Sciences, Inc
Price
Snapshot
50 fields · last close| Market Cap | $187.5B |
| P/E | 21.85 |
| Float | 1.24B |
| Beta | 0.40 |
| Volatility | 9.9% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 80 |
| Price | 150.55 |
| Change | −0.44% |
| Prev Close | 151.22 |
| Open | 150.67 |
| Day Low | 148.41 |
| Day High | 151.48 |
| Avg Vol | 5 |
| Avg $ Vol | $816.2M |
| 52W High | 157.29 |
| 52W Low | 108.46 |
| 52W Pos | 86.2% |
| From High | −4.29% |
| From Low | +38.81% |
| Max DD 1Y | −22.03% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +4.94% |
| SMA 50 | +10.65% |
| SMA 200 | +12.16% |
| RSI (14) | 68.3 |
| Vol 30D | 26.2% |
| Vol 90D | 27.9% |
| 1Y Range | 108–157 |
| Daily bars | 506 |
| Perf Week | +1.59% |
| Perf Month | +14.77% |
| Perf Quarter | +17.06% |
| Perf Half Y | +4.19% |
| Perf Year | +33.83% |
| Perf YTD | +23.81% |
| Prev Day | −0.44% |
| Clavix | A- |
| Debt / Eq | 1.10 |
| Curr Ratio | 1.55 |
| Int Cover | 120.3× |
| FCF Margin | 44.6% |
| Rev Growth | +10.2% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 3 / 35 |
What GILD does
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.
Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19.
Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program.
The company was incorporated in 1987 and is headquartered in Foster City, California.
Clavix risk grade
regraded every trading dayGILD grades A-, 80 of 100. Steadiest on Macro Resilience (68), most exposed on News Sentiment (60, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 3 of 35 in Biotechnology by Clavix score.
How rough the ride is
| GILD | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.40 | 0.50 |
| Volatilityannualized | 9.9% | 13.2% |
| Max drawdown, past yearworst peak-to-trough fall | −22.0% | — |
| Typical daily movemedian absolute daily change | 1.09% | — |
| Days beyond ±3%of the last 252 sessions | 177% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| GILD | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.40 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| GILD | |
|---|---|
| 1 week | +1.6% |
| 1 month | +14.8% |
| Year to date | +23.8% |
| 1 year | +33.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| GILD | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 5 Aug |
| Average score0 most bearish, 100 most bullish | 65 |
| Bullish · bearisharticles above 60 · below 40 | 23 · 3 |
| Directionarticles whose tone is improving vs worsening | 23 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| GILD | |
|---|---|
| Revenue growthyear over year | +10.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Biotechnology
36 companies| Metric | GILD | Sector spread | Median |
|---|---|---|---|
| Beta | 0.40 | 0.50 | |
| Volatility | 9.9% | 13.2% | |
| P/E | 21.85 | 22.77 | |
| Debt / equity | 1.10 | 0.24 | |
| Current ratio | 1.55 | 3.73 | |
| FCF margin | 44.6% | 29.1% | |
| Interest coverage | 120.3× | -0.2× |
Recent news
most recent scored articles · the chip is the article’s score · click to openGilead's quarterly dividend continues to grow and its HIV drug business is generating strong revenue, but the company relies heavily on a single blockbuster drug whose patent expires roughly a decade from now.
Gilead received FDA approval for Bixlenvo, a new single-tablet HIV treatment described as the first of its kind. The approval expands Gilead's HIV product lineup and targets patients who are currently underserved by existing options.
The FDA approved Gilead's Bixlenvo, a once-daily, single-tablet HIV treatment designed as a smaller pill option for adults already on more complex multi-drug HIV regimens.
Gilead received FDA approval for Bixlenvo, a once-daily HIV treatment that combines multiple drugs into a smaller single tablet for adults already on complex HIV drug regimens.
The FDA approved Bixlenvo, Gilead's new once-daily single-tablet HIV treatment that combines two existing Gilead drugs for adults whose virus is already suppressed but who can't use current one-pill options.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc | A- | $240.1B | 27.38 | 0.45 | Compare |
| VRTX | Vertex Pharmaceuticals Inc | B+ | $121.1B | 32.51 | 0.27 | Compare |
| REGN | Regeneron Pharmaceuticals Inc | B+ | $86.84B | 20.26 | 0.12 | Compare |
| ABBV | AbbVie Inc | B+ | $459.8B | 73.29 | 0.20 | Compare |
| MRNA | Moderna Inc | F | $59.43B | — | 1.22 | Compare |
| NTRA | Natera Inc | B- | $47.23B | — | 1.61 | Compare |
| RVMD | Revolution Medicines Inc | B- | $45.20B | — | 1.44 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C | $35.39B | 44.28 | 0.34 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.